The classic Chinese herbal pair of Danggui-Hongqi has shown certain effect in anti-myocardial fibrosis, but the underlying mechanisms remain unclear.

To explore the mechanisms underlying the effects of the Danggui-Hongqi herbal pair against myocardial fibrosis.

We searched the Web of Science Core Collection (WoSCC) to analyze the publication trends of literature on myocardial fibrosis. We used the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) to identify the major bioactive compounds of the Chinese herbal pair of Danggui-Hongqi. GeneCards.org was used to screen drug-disease intersection target genes, followed by GO enrichment analysis and KEGG enrichment analysis. Molecular docking technology was employed to dock the core proteins with the major bioactive compounds of Chinese herbal pair of Danggui-Hongqi.

From 1992 to 2022, the number of publications on myocardial fibrosis in the WoSCC showed an increasing trend. A total of 13 major bioactive compounds of Chinese herbal pair of Danggui-Hongqi and 148 drug-disease intersection target genes were obtained. GO enrichment analysis indicated that, the effect in anti-myocardial fibrosis of Chinese herbal pair of Danggui-Hongqi involve biological processes such as responses to reactive oxygen species, drug responses, lipopolysaccharide responses, and oxidative stress responses. KEGG enrichment analysis showed that, the effect in anti-myocardial fibrosis of Chinese herbal pair of Danggui-Hongqi were mainly associated with inflammation-related signaling pathways, including the interleukin-17 signaling pathway, tumor necrosis factor signaling pathway, and hypoxia-inducible factor-1 signaling pathway. Molecular docking results showed that, the binding energies between the top three major bioactive compounds of Chinese herbal pair of Danggui-Hongqi (quercetin, β-sitosterol, and stigmasterol) and the top three core proteins (MAPK3, JUN, and MAPK1) were all less than 0 kcal/mol.

Myocardial fibrosis is one of the future research hotspots and directions. The Chinese herbal pair of Danggui-Hongqi exerts anti-myocardial fibrosis effect through various biological processes and multiple signaling pathways, with its major bioactive compounds, quercetin, β-sitosterol, and stigmasterol, being potential candidate drug molecules.

经典药对当归-红芪具有一定抗心肌纤维化作用，但其作用机制尚不明确。

探讨当归-红芪药对抗心肌纤维化的作用机制。

检索Web of Science核心合集（WoSCC），分析以心肌纤维化为主题的文献发表情况；通过中药系统药理学数据库与分析平台（TCMSP）检索当归-红芪药对的主要生物活性化合物，通过基因卡数据库筛选药物-疾病交集靶标基因，并进行GO富集分析、KEGG富集分析。利用分子对接技术将核心蛋白与当归-红芪药对主要生物活性化合物进行分子对接。

1992—2022年WoSCC中以心肌纤维化为主题的文献发表数量呈逐年升高趋势。共获得13种当归-红芪药对的主要生物活性化合物、148个药物-疾病交集靶标基因。GO富集分析结果显示，当归-红芪药对抗心肌纤维化作用涉及对活性氧的反应、对药物的反应、脂多糖反应、氧化应激反应等生物学过程；KEGG富集分析结果显示，当归-红芪药对抗心肌纤维化作用主要与白介素17信号通路、肿瘤坏死因子信号通路、缺氧诱导因子1信号通路等炎症相关信号通路有关。分子对接技术结果显示，度值排在前三的主要生物活性化合物（槲皮素、β-谷甾醇、豆甾醇）与度值排在前三的核心蛋白（丝裂原活化蛋白激酶3、JUN原癌基因、丝裂原活化蛋白激酶1）之间的结合能均<0 kcal/mol。

心肌纤维化是未来研究热点和方向之一，当归-红芪药对通过多种生物学过程、多种途径发挥抗心肌纤维化作用，其主要生物活性化合物槲皮素、β-谷甾醇、豆甾醇属于候选药物分子。